Clinical Research Directory
Browse clinical research sites, groups, and studies.
Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
Sponsor: National Medical Research Radiological Centre of the Ministry of Health of Russia
Summary
The aim of the current trial is to evaluate the efficacy and safety of flat-dose nivolumab (40 mg) in combination with AVD in the management of patients with newly diagnosed advanced classic Hodgkin Lymphoma
Official title: Flat-dose Nivolumab (40 mg) in Combination With Doxorubicin, Vinblastine, and Dacarbazine (AVD) for Newly Diagnosed Advanced Classic Hodgkin Lymphoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
54
Start Date
2025-04-15
Completion Date
2029-01
Last Updated
2025-11-26
Healthy Volunteers
No
Conditions
Interventions
Nivolumab
40 mg day 1 and 15
Doxorubicin
25 mg/m2 day 1 and 15
Vinblastine
6 mg/m2 (not exceeding 10 mg) day 1 and 15
Dacarbazine
375 mg/m2 day 1 and 15
Locations (1)
P. Hertsen Moscow Oncology Research Institute (MORI) for administrative and economic work - the branch of the FSBI "National Medical Research Radiological Centre" (NMRRC) of the Ministry of Health of the Russian Federation
Moscow, Russia